Kura Oncology, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $67.5M | $53.9M | $0 |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin | — | — | — |
| Operating Expenses | |||
| Research & Development | $251.1M | $170.0M | $115.2M |
| SG&A Expense | $120.0M | $77.1M | $50.6M |
| Operating Income | $-303.6M | $-193.2M | $-165.8M |
| Operating Margin | -449.9% | -358.5% | — |
| Interest Expense | — | — | $1.5M |
| Pretax Income | $-278.4M | $-172.0M | $-152.6M |
| Income Tax Expense | $297.0K | $2.0M | $0 |
| Net Income | $-278.7M | $-174.0M | $-152.6M |
| Net Margin | -412.9% | -322.9% | — |
| EPS (Basic) | $-3.18 | $-2.02 | $-2.08 |
| EPS (Diluted) | $-3.18 | $-2.02 | $-2.08 |
| Shares Outstanding (Basic) | 87.7M | 86.2M | 73.2M |
| Shares Outstanding (Diluted) | 87.7M | 86.2M | 73.2M |
| Dividends Per Share | — | — | — |